On June 27, 2019, Health Canada published Drug and medical device highlights 2018: Helping you maintain and improve your health, an annual highlights report for 2018. The report provides information regarding Health Canada drug (human or veterinary use) and medical device approvals, as well as published safety issues in 2018. In summary, in 2018, Health Canada approved 78 new drugs for human use (40 involving new active substances), 135 new generic drugs, and 4 biosimilars.
Moreover, the Therapeutic Products Directorate (TPD) and the Biologics and Genetic Therapies Directorate (BGTD) released their Drug Submission Performance Annual Reports for the 2018-2019 Fiscal Year, which include information and statistics relating to drug submission review activity from April 1, 2018 to March 31, 2019.
Related Publications & Articles
-
Medical devices updates: mandatory use of the regulatory enrolment process for medical devices and updated guidance documents related to the regulatory enrolment process
Health Canada released a notice to industry on April 24, 2026, outlining that manufacturers must use the Regulatory Enrolment Process (REP) and Common Electronic Submission Gateway (CESG) for medical ...Read More -
Health Canada seeks feedback on phased implementation of the incorporated by reference list for Ministerial Reliance Order
As previously reported, Health Canada has proposed a Ministerial Reliance Order that would allow Health Canada to rely on decisions of foreign regulatory authorities (FRAs). Health Canada has proposed...Read More -
Health Canada finalizes biosimilar guidance: comparative clinical efficacy studies not typically required
In Canada, biosimilar products are approved by way of a new drug submission, following Health Canada guidance first released in 2010 and significantly revised in 2016.Read More
